SteadyMed Submits Type A Meeting Request Package to FDA
28 sept. 2017 08h30 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., Sept. 28, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed Receives Refusal to File Letter from FDA for Trevyent® New Drug Application
31 août 2017 06h45 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., Aug. 31, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed Reports Second Quarter 2017 Financial Results and Provides Corporate Update
11 août 2017 08h30 HE
|
SteadyMed Therapeutics
Submitted New Drug Application for Trevyent for the Treatment of Pulmonary Arterial Hypertension On track for Mid-2018 U.S. Commercial Launch, Subject to FDA Approval SAN RAMON, Calif., Aug. 11,...
SteadyMed to Present at the 2017 Wedbush PacGrow Healthcare Conference
09 août 2017 08h30 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed Appoints Jeff Myers M.D. Ph.D. Vice President of Medical Affairs
31 juil. 2017 08h30 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed Submits New Drug Application for Trevyent®
30 juin 2017 14h35 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., June 30, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed to Present at the 2017 JMP Securities Life Sciences Conference
13 juin 2017 08h30 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., June 13, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed Raises Additional Capital from Key Institutional Shareholder
26 mai 2017 08h42 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., May 26, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed Reports First Quarter 2017 Financial Results and Provides Corporate Update
12 mai 2017 08h30 HE
|
SteadyMed Therapeutics
Raised $28.2 Million in Net Proceeds in a Private PlacementReceived a Favorable IPR Ruling Invalidating United Therapeutics’ ‘393 PatentCompleted a Clinical Validation Study for Trevyent®On Track to...
SteadyMed Receives USPTO Notice of Allowance for Patent Related to Key PatchPump® Technology
02 mai 2017 08h30 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., May 02, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...